News

Shape Therapeutics’ SHP-201, an experimental gene therapy for Parkinson’s disease, significantly reduced the levels of alpha-synuclein — a protein that plays a key role in the development of the neurodegenerative condition — in the brain of mouse and nonhuman primate models, according to new preclinical data released by…

WTX-607, an oral small molecule being developed by Wavebreak, binds to and blocks the formation of small alpha-synuclein protein clumps — toxic aggregates linked to nerve damage in  Parkinson’s disease and Lewy body dementia — in human brain tissue, according to new data released by the company. The…

An experimental therapy being developed by Herantis Pharma for Parkinson’s disease was well tolerated and able to penetrate the blood-brain barrier (BBB), a semipermeable membrane that prevents certain substances, including medications, from entering the brain. That’s according to top-line data from a Phase 1b trial (NCT06659562), which…

ARV-102, an oral therapy Arvinas is developing for people with Parkinson’s disease, was shown to reach the brain — where it is needed — and to be safe and well tolerated over two weeks in clinical studies with healthy volunteers and patients. In the volunteers taking part in…

The oral therapy GT-02287, being developed by Gain Therapeutics for people with Parkinson’s disease with or without mutations in the GBA1 gene, was shown to ease motor symptoms and help patients maintain routine daily activities over three months while being safe and well tolerated. That’s according to interim…

Bemdaneprocel, a novel stem cell-derived therapy being developed by Bluerock Therapeutics, maintained a favorable safety profile and good tolerability in people with Parkinson’s disease over three years in a Phase 1 trial, new data show. Importantly, the long-term findings from the completed exPDite study (NCT04802733) also show…

More than 80% of the people with Parkinson’s disease caused by GBA1 gene mutations who are enrolled in a Phase 2 clinical trial have completed one year of treatment with Bial’s experimental candidate BIA 28-6156. The study, called ACTIVATE (NCT05819359), is assessing the treatment’s safety and efficacy…

The experimental oral therapy VQ-101 can successfully restore a critical cellular function in people with a genetic form of Parkinson’s disease, the treatment’s developer, Vanqua Bio, has announced. One month of daily treatment with VQ-101 safely and robustly boosted the activity of the glucocerebrosidase (GCase) enzyme in patients…

Neurosurgeons temporarily implanted a tiny device into the brains of three people with Parkinson’s disease to collect data on a poorly known brain region, with the goal of understanding how Parkinson’s affects executive function. Doctors at the University of Colorado Anschutz — the first site authorized by the U.S.

Pharmather is planning to meet with the U.S. Food and Drug Administration (FDA) in hopes of reaching an agreement on the design of a future Phase 3 clinical trial testing its generic ketamine product Ketarx in individuals with Parkinson’s disease. The plans were mentioned in a company…